article thumbnail

Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More

Xconomy

Biogen’s (NASDAQ: BIIB ) earnings call this week was the first since its Alzheimer’s drug aducanumab failed in a Phase 3 study and eviscerated the company’s shares. But it’s earnings season now, so some of them don’t have much choice. CEO Michel Vounatsos acknowledged the drug didn’t work.

News 94
article thumbnail

Bio Roundup: 2019 Trials, Pilgrim Price Chat, Pre-Xmas Sales & More

Xconomy

It’s beginning to look a lot like, well, the last roundup of the year, with plenty of news to pack in before our holiday breather.

Pricing 73
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Max Q: How to build a Starship

TechCrunch LA

Lots of other news, too, including our own: We announced this week that NASA Administrator Jim Bridenstine is going to be our guest on stage at TC Sessions: Space coming up in June. And if you have to ask about the price, you probably can’t afford it. New platform headed to the ISS in March. Farewell to a legend.

SpaceX 153
article thumbnail

Bio Roundup: RIP Roger Tsien, Novartis CAR-T Wheel, Zika News & More

Xconomy

For more on Tsien and the rest of the week’s news, let’s get to the roundup. The companies—Amgen, Sanofi, and Regeneron Pharmaceuticals—are due to release important long-term data next year that will shape the debate over the drugs’ prices.

News 57
article thumbnail

Bio Roundup: Cancer Wishes and Shopping Lists, Allergan Pricing & More

Xconomy

For more on that and the rest of the week’s news, fire up the roundup rockets. —One cancer screening test got positive news from a federal agency. The application could put Agios well ahead of typical cancer drug development timelines; shares spiked more than 20 percent on the news.

Pricing 40
article thumbnail

Bio Roundup: Drug Pricing, Cystic Fibrosis Showdown, Myovant & More

Xconomy

In the meantime, however, the news hasn’t been all bad for drugmakers. And new treatments to expand the reach of cystic fibrosis therapies have begun clinical testing. The news came with some caveats, however, as TheStreet.com explains here. THIS WEEK IN DRUG PRICING…. AND IN OTHER NEWS…. difficile infection.

Pricing 40
article thumbnail

As U.S. Looks to Launch Precision Health Study, Google’s Role Emerges

Xconomy

government has ambitious plans for a long-term health study with one million Americans, and one of the world’s most powerful tech companies has a big part to play, including the storage of all the data on its “cloud” servers. It even has a price guide.). ” Verily’s role has since shifted, however.

PMI 40